Three ÐǺ£ÆåÅÆ employees engage in friendly conversation during a presentation.
Three ÐǺ£ÆåÅÆ employees engage in friendly conversation during a presentation.

Investor Relations

ÐǺ£ÆåÅÆ is a fast-growing international biotech company committed to improving people’s lives with our differentiated antibody medicines.

Share Information
Annual General Meeting 2025
The Annual General Meeting 2025 took place on Wednesday, March 12, 2025, at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, 1560 Copenhagen, Denmark. 
Latest news
Apr 28, 2025 at 02:16 PM CEST
Transactions in Connection with Share Buy-back Program
Apr 22, 2025 at 01:23 PM CEST
Transactions in Connection with Share Buy-back Program
Apr 15, 2025 at 12:22 PM CEST
ÐǺ£ÆåÅÆ Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025
Apr 28, 2025 at 02:16 PM CEST
Transactions in Connection with Share Buy-back Program
Apr 22, 2025 at 01:23 PM CEST
Transactions in Connection with Share Buy-back Program
Apr 15, 2025 at 12:22 PM CEST
ÐǺ£ÆåÅÆ Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025
Upcoming Events
May 8, 2025
Aug 7, 2025
Nov 6, 2025
A ÐǺ£ÆåÅÆ employee smiles in conversation with another coworker.
ÐǺ£ÆåÅÆ ÐǺ£ÆåÅÆ
ÐǺ£ÆåÅÆ at a glance
ÐǺ£ÆåÅÆ is an international biotechnology company that develops innovative antibody products, with the vision that our knock-your-socks-off antibody treatmentsTM transform the treatment of cancer and other serious diseases.
Two employees work together on laptops in a bright open office environment.
Reports
2024 ÐǺ£ÆåÅÆ Annual Report
Download ÐǺ£ÆåÅÆ’s latest annual report.

Contact Investor Relations

Our aim is to deliver reliable and transparent information to our shareholders. If you have questions about ÐǺ£ÆåÅÆ, our products or other relevant shareholder information, please use the information below to contact us. We will handle your personal data in accordance with our Privacy Policy.
Headshot of Andrew Carlsen, Vice President and Head of Investor Relations at ÐǺ£ÆåÅÆ
Andrew Carlsen
Vice President, Head of Investor Relations

Email

acn@genmab.com

Telephone

+45 3377 9558

Address

Carl Jacobsens Vej 30
2500 Valby
Denmark

For general investor relations enquiries please contact ir@genmab.com.
Key Documents
Corporate Responsibility & Sustainability Highlights 2024
ÐǺ£ÆåÅÆ Investor Presentation - March 2025
Investor Fact Sheet
Articles of association dated March 12, 2025 – English
Voting Results of the Annual General Meeting 2025
AGM 2025 Presentation
Useful links
Investor Resources
Environmental, Social and Governance
ÐǺ£ÆåÅÆ ÐǺ£ÆåÅÆ